Drug Trial Radar · NCT07914231
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Coultreon BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess how-well COL-5671-PRO works (clinical efficacy), how safe it is (safety), and how well it is tolerated (tolerability) when compared to placebo (a look-alike substance that contains no drug) in adults with moderate-to-severe plaque psoriasis Participants will take drug COL-5671 or a placebo every day for 12 weeks.
Conditions
- Plaque Psoriasis
Interventions
COL-5671-PRODrug
COL-5671-PRO oral capsules
PlaceboDrug
Matching placebo to COL-5671-PRO capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of 75% in PASI score relative to baseline (PASI75) at Week 12Time frame: From enrollment to the end of treatment at 12 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Lynderm Research Inc.
Markham, Canada
DermEdge Cutting-edge Dermatology
Mississauga, Canada
SKiN Centre for Dermatology
Peterborough, Canada
Centre de Recherche Dermatologique due Quebec Metropolitain Inc.
Québec, Canada
The Centre for Dermatology
Richmond Hill, Canada
Skinsense Medical Research
Saskatoon, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.